Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273) - Business Wire
- Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273) Business Wire
- Moderna says company has enough cases to provide analysis on its Covid-19 vaccine trial CNBC Television
- Moderna's Cancer Vaccine Scores in a Clinical Trial Motley Fool
- Moderna says it has completed its Phase 3 trial for COVID-19 vaccine Yahoo News
- Moderna Poised to Take Vaccine Spotlight With Data Due Bloomberg
- View Full Coverage on Google News